Страна: САЩ
Език: английски
Източник: NLM (National Library of Medicine)
TAMSULOSIN HYDROCHLORIDE (UNII: 11SV1951MR) (TAMSULOSIN - UNII:G3P28OML5I)
Blenheim Pharmacal, Inc.
TAMSULOSIN HYDROCHLORIDE
TAMSULOSIN HYDROCHLORIDE 0.4 mg
ORAL
PRESCRIPTION DRUG
Tamsulosin hydrochloride capsules are indicated for the treatment of the signs and symptoms of benign prostatic hyperplasia (BPH) [see Clinical Studies (14) ]. Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension. Tamsulosin hydrochloride capsules are contraindicated in patients known to be hypersensitive to tamsulosin hydrochloride or any component of tamsulosin hydrochloride capsules. Reactions have included skin rash, urticaria, pruritus, angioedema and respiratory symptoms [see Adverse Reactions (6.2) ]. - Contraindicated in patients known to be hypersensitive to tamsulosin hydrochloride or any component of tamsulosin hydrochloride capsules (4, 6.2) - Pediatric Use: Not indicated for use in pediatric populations (8.4, 12.3) - Geriatric Use: No overall differences in efficacy or safety vs. younger patients, but greater sensitivity of some older adults cannot be ruled out (8.5, 12.3) - Renal Impairment: Has not been studied in patients with end stage renal disease (8.6, 12.3
Tamsulosin hydrochloride capsules USP, 0.4 mg are supplied in high density polyethylene bottles containing 30 or 500 size '2', hard gelatin capsules with olive green opaque cap and orange opaque body, filled with white to off-white pellets. The capsules are imprinted with “W” on the cap with black ink. 516 Tamsulosin hydrochloride capsules USP, 0.4 mg, 30 capsules (NDC 64679-516-01) Tamsulosin hydrochloride capsules USP, 0.4 mg, 100 capsules (NDC 64679-516-02) Tamsulosin hydrochloride capsules USP, 0.4 mg, 500 capsules (NDC 64679-516-03) Tamsulosin hydrochloride capsules USP, 0.4 mg, 16 (2 x 8) unit dose blister carton (NDC 64679-516-04) Tamsulosin hydrochloride capsules USP, 0.4 mg, 30 (1 x 30) unit dose blister carton (NDC 64679-516-05) Store at 20° to 25°C (68°C to 77°F) [See USP Controlled Room Temperature]. Keep tamsulosin hydrochloride capsules, USP and all medicines out of reach of children.
Abbreviated New Drug Application
TAMSULOSIN HYDROCHLORIDE- TAMSULOSIN HYDROCHLORIDE CAPSULE BLENHEIM PHARMACAL, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE TAMSULOSIN HYDROCHLORIDE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR TAMSULOSIN HYDROCHLORIDE. TAMSULOSIN HYDROCHLORIDE CAPSULES USP*, 0.4 MG INITIAL U.S. APPROVAL: 1997 RECENT MAJOR CHANGES Dosage and Administration (2) 4/2009 Contraindications (4) 12/2009 Warnings and Precautions Drug Interactions (5.2) 12/2009 Screening for Prostate Cancer (5.4) 12/2009 INDICATIONS AND USAGE Tamsulosin hydrochloride is an alpha adrenoceptor antagonist indicated for treatment of the signs and symptoms of benign prostatic hyperplasia (1) Tamsulosin hydrochloride capsules are not indicated for the treatment of hypertension (1) SEE 17 FOR PATIENT COUNSELING INFORMATION AND PATIENT COUNSELING INFORMATION. REVISED: 10/2015 FULL PRESCRIBING INFORMATION: CONTENTS* 1 INDICATIONS AND USAGE 2 DOSAGE AND ADMINISTRATION 3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS 5 WARNINGS AND PRECAUTIONS 5.1 Orthostasis 5.2 Drug Interactions 5.3 Priapism 5.4 Screening for Prostate Cancer 5.5 Intraoperative Floppy Iris Syndrome 5.6 Sulfa Allergy 6 ADVERSE REACTIONS 6.1 Clinical Trials Experience 6.2 Postmarketing Experience 7 DRUG INTERACTIONS 7.1 Cytochrome P450 Inhibition 7.2 Other Alpha Adrenergic Blocking Agents 7.3 PDE5 Inhibitors 7.4 Warfarin 7.5 Nifedipine, Atenolol, Enalapril 7.6 Digoxin and Theophylline 7.7 Furosemide 8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy 8.3 Nursing Mothers 1 8.4 Pediatric Use 8.5 Geriatric Use 8.6 Renal Impairment 8.7 Hepatic Impairment 10 OVERDOSAGE 11 DESCRIPTION 12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES 16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION 17.1 Hypotension 17.2 Priapism 17.3 Screening for Prostate Cancer 17.4 Intrao Прочетете целия документ